Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials

The use of overall survival (OS) as the gold standard primary end-point (PEP) in metastatic oncologic randomised controlled trials (RCTs) has declined in favour of progression-free survival (PFS) without a complete understanding of the degree to which PFS reliably predicts for OS.

Source: European Journal of Cancer - July 19, 2020 Category: Cancer & Oncology Authors: Dario Pasalic, Gwendolyn J. McGinnis, C. David Fuller, Aaron J. Grossberg, Vivek Verma, Walker Mainwaring, Austin B. Miller, Timothy A. Lin, Amit Jethanandani, Andres F. Espinoza, Markus Diefenhardt, Prajnan Das, Vivek Subbiah, Ishwaria M. Subbiah, Reshma Tags: Original Research Source Type: research